|
US 12,006,307 B2 |
|
| Pharmaceutical compounds for treatment of medical disorders |
| Jason Allan Wiles, Madison, CT (US); Avinash S. Phadke, Branford, CT (US); Milind Deshpande, Madison, CT (US); Atul Agarwal, Hamden, CT (US); Dawei Chen, Guilford, CT (US); Venkat Rao Gadhachanda, Hamden, CT (US); Akihiro Hashimoto, Branford, CT (US); Godwin Pais, Hamden, CT (US); Qiuping Wang, Bethany, CT (US); Xiangzhu Wang, Branford, CT (US); Joel Charles Barrish, Richboro, PA (US); William Greenlee, Teaneck, NJ (US); and Kyle J. Eastman, New Haven, CT (US) |
| Assigned to Achillion Pharmaceuticals, Inc., Boston, MA (US) |
| Filed by Achillion Pharmaceuticals, Inc., Boston, MA (US) |
| Filed on Jul. 25, 2022, as Appl. No. 17/872,104. |
| Application 17/872,104 is a continuation of application No. 16/555,946, filed on Aug. 29, 2019, granted, now 11,447,465, issued on Sep. 20, 2022. |
| Application 16/555,946 is a continuation of application No. PCT/US2018/020530, filed on Mar. 1, 2018. |
| Claims priority of provisional application 62/466,290, filed on Mar. 2, 2017. |
| Claims priority of provisional application 62/466,308, filed on Mar. 2, 2017. |
| Claims priority of provisional application 62/465,754, filed on Mar. 1, 2017. |
| Claims priority of provisional application 62/465,799, filed on Mar. 1, 2017. |
| Prior Publication US 2023/0071620 A1, Mar. 9, 2023 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 403/10 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 493/04 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01); C07F 9/6558 (2006.01) |
